-
Selective estrogen receptor modulators (SERMs) like tamoxifene and raloxifene are now well-established therapeutics, and new agents such as bazedoxifene and ospemifene have recently been introduced. These new agents have unique tissue-specific profiles that allow for a customization of therapeutic effect. In this review, the profiles of bazedoxifene and ospemifene will be compared and discussed relevant to their place in clinical practice.
-
Hereditary ovarian cancer syndromes are uncommon, but are most often represented by mutation in BRCA1/2.
-
Davis and colleagues report the results of a one-year, randomized, controlled clinical trial of 814 women not on estrogen therapy from 65 centers in the United States, Canada, Australia, the United Kingdom, and Sweden with hypoactive sexual desire disorder treated with transdermal testosterone, 150 or 300 µg per day, or placebo.
-
The authors present a series of gynecological conditions that are effectively diagnosed by hysteroscopy, including adenomyosis, chronic endometritis, Mullerian anomalies, retained fetal bones, endocervical ossification, and intrauterine abnormalities. In addition, they note that hysteroscopy can be a major part of the treatment for these conditions.
-
The adverse publicity following publications from the Women's Health Initiative was a multibillion dollar bonanza for compounding pharmacies providing postmenopausal hormones.
-
In this issue: The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
-
Zaman et al randomized 340 pregnant Bangladeshi women to receive either inactivated influenza or pneumococcal polysaccharide (control group) vaccine.
-
This interesting study just surfaced in the British Journal of Obstetrics and Gynecology that addressed the relationship between spastic cerebral palsy (CP) and asphyxia-related causes.
-
In the issue: 5-á reductase inhibitors and hip fracture in men; the effects of drug-reimbursement policy on outcomes; new guidelines for type 2 diabetes; beta-blocker-associated brady-cardia is linked to CVD events; FDA Updates.
